MEDIUM confidence: 100% data completeness, but the composite (58) sits in the indecisive 30–70 range — strong-buy and short calls require a more decisive composite. What does confidence mean?
Technical context for active traders — derived from price, the 50/200-day moving averages, the 52-week range, and recent volume. Not part of the QScore.
Fama-French 5-factor (2×3) + Momentum, monthly OLS with Newey-West errors. Bars show signed factor betas; faded bars/figures aren't statistically significant.
AI classification of policy/regulatory sensitivity from the company's sector, industry, and business description. Exposure/sensitivity only — not a political opinion, a prediction of government action, or investment advice. As of 2026-07-10.
Dated events from the market calendar; the “also watch” items are AI-generated observations from QScoring data. Informational only — not investment advice, and dates can change.
Avg target $280 (last qtr, 14 analysts) → $284 (last mo, 13) (+1.3%).
Buy-rated share 91% → 86% over ~3 months (-5pp).
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jul 2026 | $4.26 | $6.12 | +43.7% |
| Apr 2026 | $4.17 | $4.82 | +15.6% |
| Feb 2026 | $4.07 | $4.70 | +15.5% |
| Oct 2025 | $3.34 | $3.70 | +10.8% |
| Jul 2025 | $2.87 | $4.02 | +40.1% |
| Apr 2025 | $3.12 | $4.36 | +39.7% |
| Feb 2025 | $2.95 | $3.44 | +16.6% |
| Oct 2024 | $2.33 | $2.93 | +25.8% |
| Metric (USD) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $19.5B— | $19.2B-1.6% | $20.5B+7.2% | $20.7B+0.6% | $21.3B+3.1% |
| EPS (dil.) | $8.42— | $3.79-55.0% | $5.71+50.7% | $32.70+472.7% | $15.49-52.6% |
| Free Cash Flow | $910M— | $321M-64.7% | $1.6B+405.6% | $1.1B-31.2% | $2.5B+126.7% |
| Gross Margin | 37.3% | 36.8%-0.5pp | 38.0%+1.2pp | 39.7%+1.7pp | 82.3%+42.5pp |
| Operating Margin | 14.7% | 12.2%-2.6pp | 12.2%+0.0pp | 28.8%+16.6pp | 16.1%-12.7pp |
| Net Margin | 4.7% | 2.1%-2.5pp | 3.0%+0.8pp | 15.5%+12.5pp | 6.6%-8.9pp |
Absolute figures with year-over-year change. Margins show the level with the change in percentage points (pp). “n/m” = not meaningful (prior ≤ 0); ⚠ marks a large percentage off a small base — read the dollar figure.
Net buyback (repurchases less issuance) ÷ market cap, plus trailing dividend yield.
Working the DCF backward: holding the assumptions below, this is the free-cash-flow growth today's price implies over the next 10 years. It is a read on the price's embedded expectations — not a fair-value or target price.
The price implies FCF growth below the analyst consensus of 3.2%/yr (revenue basis).
Base free cash flow $1.8B (avg FY2023–FY2025; latest year $2.5B) · equity value $21.5B · levered FCF discounted at the cost of equity. Reverse DCF is illustrative, not advice.
Net insider -$16.0M over 180 days (0 open-market buys, 18 sells). Insider buying is the informative signal; routine selling is normal.
Short interest, days-to-cover, and institutional-ownership change require a data-plan upgrade (not yet available).
Forward-return IC, quintile spread & hit rate publish on /performance as the tracking panel accrues enough no-look-ahead history.
The QScore of 58 for Tenet Healthcare Corporation suggests a moderately attractive stock, driven by strong momentum and profitability scores of 73 and 61, respectively. The stock exhibits strong momentum, with a 12-month return of 56.7% and a bullish 50-day versus 200-day moving average trend. In contrast, the growth score is lower at 46, due in part to a decline in EPS growth of -52.7%. The long-term and short-term scores are relatively close, with the short-term score 6 points higher at 61, indicating some near-term optimism.